Lantheus Holdings, Inc. $LNTH Shares Sold by LSV Asset Management

LSV Asset Management reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 23.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 283,800 shares of the medical equipment provider’s stock after selling 86,800 shares during the period. LSV Asset Management owned about 0.42% of Lantheus worth $23,232,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Cerity Partners LLC raised its position in shares of Lantheus by 12.7% in the first quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider’s stock worth $1,143,000 after acquiring an additional 1,323 shares during the period. Signaturefd LLC raised its stake in Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 116 shares during the period. Victory Capital Management Inc. lifted its holdings in Lantheus by 41.2% in the first quarter. Victory Capital Management Inc. now owns 123,067 shares of the medical equipment provider’s stock valued at $12,011,000 after acquiring an additional 35,937 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of Lantheus during the 1st quarter worth $898,000. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in Lantheus by 2.1% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 33,884 shares of the medical equipment provider’s stock worth $3,307,000 after buying an additional 695 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on LNTH shares. JMP Securities dropped their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. TD Cowen cut their price target on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, September 15th. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Mizuho reduced their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Finally, B. Riley reduced their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $74.17.

Lantheus Stock Up 1.9%

LNTH opened at $53.50 on Wednesday. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The business’s fifty day moving average is $53.85 and its two-hundred day moving average is $65.73. The company has a market cap of $3.55 billion, a price-to-earnings ratio of 14.23 and a beta of 0.04.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.